Literature DB >> 7489969

Proteolytic activity of NS3 serine proteinase of hepatitis C virus efficiently expressed in Escherichia coli.

I Shoji1, T Suzuki, S Chieda, M Sato, T Harada, T Chiba, Y Matsuura, T Miyamura.   

Abstract

The serine proteinase of hepatitis C virus (HCV) non-structural protein NS3 was efficiently expressed in an active form as a fused protein with oligohistidine in Escherichia coli. The recombinant fusion protein was purified to near homogeneity by affinity chromatography on a metal chelation column. Trans-cleavage activity of this protein was investigated by using the substrate NS5 protein expressed in insect cells. The purified serine proteinase trans-cleaved the partially purified NS5 protein. In contrast, the NS3 proteins with mutations at the proposed catalytic site, Ser1165 or His1083, lost the trans-cleavage activity. Analysis of the authentic enzyme and variants with site-directed mutations provides a useful tool for understanding the structure-function relationship of the NS3 serine proteinase. We then developed an in vivo trans-cleavage assay system by coexpression of the NS3 proteinase and the NS5 substrate in E coli, and examined the effect of known inhibitors of serine proteinase. Inhibition of its proteolytic activity by N-p-tosyl-L-lysine chloromethyl ketone (TLCK) was observed, but only at high concentrations. The in vitro and in vivo trans-cleavage assays for NS3 serine proteinase will facilitate efficient testing for inhibitors of the replication of HCV and specific treatment for hepatitis C.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489969

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  Conformational changes in the NS3 protease from hepatitis C virus strain Bk monitored by limited proteolysis and mass spectrometry.

Authors:  S Orrù; F Dal Piaz; A Casbarra; G Biasiol; R De Francesco; C Steinkühler; P Pucci
Journal:  Protein Sci       Date:  1999-07       Impact factor: 6.725

Review 2.  Perspectives for the treatment of infections with Flaviviridae.

Authors:  P Leyssen; E De Clercq; J Neyts
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

3.  Establishment of a simple assay in vitro for hepatitis C virus NS3 serine protease based on recombinant substrate and single-chain protease.

Authors:  Gui-Xin Du; Li-Hua Hou; Rong-Bin Guan; Yi-Gang Tong; Hai-Tao Wang
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

4.  Synthetic antigens representing the antigenic variation of human hepatitis C virus.

Authors:  Kyung Hee Kang; Yasuhiro Yamamura; Maria P Carlos; Nicolas Karvelas; In-Sup Kim; Deepa Sunkara; Rebecca Rivera; Murray B Gardner; David E Anderson; Francisco Diaz-Mitoma; José Torres; Juan P Marquez
Journal:  Viral Immunol       Date:  2010-10       Impact factor: 2.257

5.  Chimeric Sindbis viruses dependent on the NS3 protease of hepatitis C virus.

Authors:  G Filocamo; L Pacini; G Migliaccio
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

6.  Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease.

Authors:  S S Taremi; B Beyer; M Maher; N Yao; W Prosise; P C Weber; B A Malcolm
Journal:  Protein Sci       Date:  1998-10       Impact factor: 6.725

7.  Activity of purified hepatitis C virus protease NS3 on peptide substrates.

Authors:  C Steinkühler; A Urbani; L Tomei; G Biasiol; M Sardana; E Bianchi; A Pessi; R De Francesco
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

Review 8.  The Discovery and Development of Boceprevir: A Novel, First-generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease.

Authors:  Anita Y M Howe; Srikanth Venkatraman
Journal:  J Clin Transl Hepatol       Date:  2013-09-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.